SOURCE: AtheroNova Inc.

AtheroNova Inc.

February 22, 2011 08:45 ET

AtheroNova Inc. Atherosclerotic Plaque Regression Study Commenced at The David Geffen School of Medicine at the University of California Los Angeles (UCLA)

IRVINE, CA--(Marketwire - February 22, 2011) - AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced that the Company's second round preclinical atherosclerotic plaque regression study has commenced at The David Geffen School of Medicine at UCLA.

The study is an adjunct to an additional second round preclinical trial currently being conducted for the Company at the Cedars-Sinai Heart Institute's Division of Cardiology. The studies are expected to be completed within approximately six months. 

About AtheroNova

AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a development stage company currently researching novel patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The Company plans to develop multiple applications for its compounds, to be used in pharmaceutical grade products for the treatment of atherosclerosis.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the preclinical trials being conducted for the Company by UCLA and Cedars Sinai, the expected time to completion of the research, and the development of applications for AtheroNova's compounds. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

  • Company contact:

    Thomas Gardner
    Chief Executive Officer
    (949) 476-1100

    Mark Selawski
    Chief Financial Officer
    (949) 476-1100

    Investor Contact

    Leon Hamerling
    Investor Media Group
    (877) 725-2500